- $3.49m
- $2.31m
- $7.42m
NASDAQ RESUMED AT 01:46 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:36 PM
NASDAQ RESUMED AT 01:35 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:15 PM
Brief: BioNexus Gene Lab Corp - Matthew L. Barsing Appointed As Chairman Of Chemrex Board - SEC Filing
Brief: Bionexus Gene Lab Completes Strategic Investment In Fidelion Diagnostics Secures 15% Equity Stake In Global Ai-Oncology Platform
Brief: Bionexus Gene Lab Corp - Enters $500 Million Equity Purchase Agreement
Brief: Bionexus Gene Lab Corp - To Pay $2 Million License Fee To Fidelion
Brief: Bionexus Gene Lab Corp Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Bionexus Gene Lab Corp Signs Strategic Partnership Term Sheet with Birchbiomed Inc.
Brief: BioNexus Gene Lab And Fidelion Announce Strategic Cross-Equity Partnership
Brief: BioNexus Gene Lab Appoints Chong Set Fui As CFO
Brief: BioNexus Gene Lab Corp Regains Nasdaq Compliance With $1.00 Minimum Bid Price
Brief: Bionexus Gene Lab Corp Announces Board Approval Of Ethereum Treasury Strategy And Release Of Strategic Whitepaper
Brief: Bionexus Gene Lab Corp -On Nov 5, Got Notification From Nasdaq, Co To Be Delisted From Nasdaq Due To Its Failure To Comply With Listing Rule
Brief: Bionexus Gene Lab Corp Announces Three-Year Agreement To Develop Biogas Projects In Malaysia
Brief: Bionexus Gene Lab Corp Announces New Business Developments For Subsidiary Chemrex With Investment In High-Quality Color Paste Production
Investment In Ascension Innovation Sdn Bhd
Brief: Bionexus Gene Lab Says Got Notice From Nasdaq That Co Is Eligible For Additional 180 Calendar Day Extension Period, Or Until Nov 4 To Regain Compliance